小剂量瑞舒伐他汀钙对老年短暂性脑缺血发作患者二级预防的疗效

被引：10

作者：

申潇竹

田昌荣

机构：

[1] 连云港市第二人民医院老年医学科

来源：

临床神经病学杂志 | 2013年 / 26卷 / 04期

关键词：

短暂性脑缺血发作; 二级预防; 瑞舒伐他汀钙; 老年人;

D O I：

暂无

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

100204 [神经病学];

摘要：

目的探讨小剂量瑞舒伐他汀钙对老年短暂性脑缺血发作(TIA)患者二级预防的疗效。方法检测103例老年TIA患者的血脂、血浆高敏C反应蛋白(hs-CRP)及同型半胱氨酸(Hcy)水平及颈动脉粥样硬化斑块状况。给予5 mg/d的瑞舒伐他汀钙进行治疗,于治疗后30 d及180 d进行复查,并随访6个月。结果与治疗前比较,治疗后30 d及180 d时患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A(Apo A)、载脂蛋白B(Apo B)、hs-CRP、Hcy均显著下降,高密度脂蛋白胆固醇(HDL-C)升高(P<0.05～0.01)。治疗第30 d时LDL-C<2.07 mmol/L的达标率为23.4%,180 d时为40.2%;治疗30 d时LDLC下降幅度>40%的达标率为30.8%,180 d时为64.2%。与治疗前比较,治疗后30 d时颈动脉内-中膜厚度(IMT)明显减少(P<0.05);治疗后180 d时IMT、低密度及混合密度斑块面积均明显减少(均P<0.01)。随访6个月内,TIA再发作11例(10.7%);出现丙氨酸转氨酶(ALT)>1倍正常上限的患者9例(8.7%),ALT>3倍正常上限1例(1.0%),天冬氨酸转氨酶(AST)>1倍正常上限8例(7.8%),AST>3倍正常上限2例(1.9%)。结论小剂量瑞舒伐他汀钙对老年TIA患者是安全有效的,适合脑卒中二级预防的长期使用。

引用

收藏

页码：264 / 267

页数：4

相关论文

共 13 条

[1]

Vegetarianism produces subclinical malnutrition, hyperhomocysteinemia and atherogenesis [J].

Ingenbleek, Yves ;

McCully, Kilmer S. .

NUTRITION, 2012, 28 (02) :148-153

[2]

Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association [J].

Furie, Karen L. ;

Kasner, Scott E. ;

Adams, Robert J. ;

Albers, Gregory W. ;

Bush, Ruth L. ;

Fagan, Susan C. ;

Halperin, Jonathan L. ;

Johnston, S. Claiborne ;

Katzan, Irene ;

Kernan, Walter N. ;

Mitchell, Pamela H. ;

Ovbiagele, Bruce ;

Palesch, Yuko Y. ;

Sacco, Ralph L. ;

Schwamm, Lee H. ;

Wassertheil-Smoller, Sylvia ;

Turan, Tanya N. ;

Wentworth, Deidre .

STROKE, 2011, 42 (01) :227-276

[3]

Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER) [J].

Nicholls, Stephen J. ;

Brandrup-Wognsen, Gunnar ;

Palmer, Mike ;

Barter, Philip J. .

AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (01) :69-76

[4]

Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack [J].

Adams, Robert J. ;

Albers, Greg ;

Alberts, Mark J. ;

Benavente, Oscar ;

Furie, Karen ;

Goldstein, Larry B. ;

Gorelick, Philip ;

Halperin, Jonathan ;

Harbaugh, Robert ;

Johnston, S. Claiborne ;

Katzan, Irene ;

Kelly-Hayes, Margaret ;

Kenton, Edgar J. ;

Marks, Michael ;

Sacco, Ralph L. ;

Schwamm, Lee H. .

STROKE, 2008, 39 (05) :1647-1652

[5]

Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis [J].

Giles, Matthew F. ;

Rothwell, Peter M. .

LANCET NEUROLOGY, 2007, 6 (12) :1063-1072

[6]

Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack [J].

Johnston, S. Claiborne ;

Rothwell, Peter M. ;

Nguyen-Huynh, Mai N. ;

Giles, Matthew F. ;

Elkins, Jacob S. ;

Bernstein, Allan L. ;

Sidney, Stephen .

LANCET, 2007, 369 (9558) :283-292

[7]

ACC/AHA/NHLBI clinical advisory on the use and safety of statins [J].

Pasternak, RC ;

Smith, SC ;

Merz, CNB ;

Grundy, SM ;

Cleeman, JI ;

Lenfant, C .

STROKE, 2002, 33 (09) :2337-2341

[8]

Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia [J].

Kinlay, S ;

Timms, T ;

Clark, M ;

Karam, C ;

Bilodeau, T ;

Ridker, PM ;

Rifai, N ;

Carlson, W ;

Lloyd-Jones, DM ;

Johnstone, M ;

Rubenstein, J ;

Alexander, S ;

Orav, J ;

Stone, PH .

AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (10) :1205-+

[9]

High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesterolemia [J].

Lüftjohann, D ;

Sigit, JI ;

Locatelli, S ;

von Bergmann, K ;

Schmidt, HHA .

ATHEROSCLEROSIS, 2001, 155 (01) :265-266

[10]

Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia [J].

Giral, P ;

Bruckert, E ;

Jacob, N ;

Chapman, MJ ;

Foglietti, MJ ;

Turpin, G .

ATHEROSCLEROSIS, 2001, 154 (02) :421-427